Toxicity of initial chemotherapy in older patients with lung cancers

od Zauderer, Marjorie G., Sima, Camelia S., Korc-Grodzicki, Beatriz, Kris, Mark G., Krug, Lee M.
Wydane 2012

Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers

od Eng, Juliana, Hsu, Meier, Chaft, Jamie E., Kris, Mark G., Arcila, Maria E., Li, Bob T.
Wydane w Lung Cancer (2016)

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

od Basch, Ethan, Hesketh, Paul J., Kris, Mark G., Prestrud, Ann Alexis, Temin, Sarah, Lyman, Gary H.
Wydane 2011

Creating a Synthetic Clinical Trial: Comparative Effectiveness Analyses Using an Electronic Medical Record

od Zauderer, Marjorie G., Grigorenko, Aleksandr, May, Paul, Kastango, Nicholas, Wagner, Isaac, Caroline, Aryeh, Kris, Mark G.
Wydane w JCO Clin Cancer Inform (2019)

Making Checkpoint Inhibitors Part of Treatment for Patients with Locally Advanced Lung Cancers: The Time is Now

od Kris, Mark G., Faivre-Finn, Corinne, Kordbacheh, Tiana, Chaft, Jamie, Luo, Jia, Tsao, Anne, Swisher, Stephen
Wydane w Am Soc Clin Oncol Educ Book (2020)

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical...

od Chaft, Jamie E., Oxnard, Geoffrey R., Sima, Camelia S., Kris, Mark G., Miller, Vincent A., Riely, Gregory J.
Wydane 2011

Phase II Study of Docetaxel and Vinorelbine as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancers

od Chaft, Jamie E., Rekhtman, Natasha, Sima, Camelia S., Rusch, Valerie, Kris, Mark G., Zakowski, Maureen, Azzoli, Christopher G.
Wydane 2013

Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma

od Mattar, Marissa S., Chang, Jason, Benayed, Ryma, Halpenny, Darragh, Powers, Astin, Kleiner, David, Drilon, Alexander, Kris, Mark G.
Wydane w Clin Lung Cancer (2019)

Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung

od Chaft, Jamie E., Sima, Camelia S., Ginsberg, Michelle S., Huang, James, Kris, Mark G., Travis, William D., Azzoli, Christopher G.
Wydane 2012

Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component

od Paik, Paul K., Varghese, Anna M., Sima, Camelia S., Moreira, Andre L., Ladanyi, Marc, Kris, Mark G., Rekhtman, Natasha
Wydane 2012

A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib

od Yu, Helena A., Perez, Leslie, Chang, Qing, Gao, Sizhi P., Kris, Mark G., Riely, Gregory J., Bromberg, Jacqueline
Wydane w J Thorac Oncol (2016)

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

od Basch, Ethan, Deal, Allison M., Dueck, Amylou C., Scher, Howard I., Kris, Mark G., Hudis, Clifford, Schrag, Deborah
Wydane w JAMA (2017)

Lungs don’t forget: Comparison of the KRAS and EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers

od Varghese, Anna M., Sima, Camelia S., Chaft, Jamie E., Johnson, Melissa L., Riely, Gregory J., Ladanyi, Marc, Kris, Mark G.
Wydane 2013

Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib

od Hellmann, Matthew D., Reva, Boris, Yu, Helena, Rusch, Valerie W, Rizvi, Naiyer A, Kris, Mark G, Arcila, Maria E
Wydane w J Thorac Oncol (2014)

Association of KRAS and EGFR Mutations with Survival in Patients with Advanced Lung Adenocarcinomas

od Johnson, Melissa L., Sima, Camelia S., Chaft, Jamie, Paik, Paul K., Pao, William, Kris, Mark G., Ladanyi, Marc, Riely, Gregory J.
Wydane 2012

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically-resected stage I-IIIA non-small cell lung cancers

od Drilon, Alexander, Sugita, Hirofumi, Sima, Camelia S., Zauderer, Marjorie, Rudin, Charles M., Kris, Mark G., Rusch, Valerie W., Azzoli, Christopher G.
Wydane 2014

KRAS Mutation is a Significant Prognostic Factor in Early Stage Lung Adenocarcinoma

od Kadota, Kyuichi, Sima, Camelia S., Arcila, Maria E., Hedvat, Cyrus, Kris, Mark G., Jones, David R., Adusumilli, Prasad S., Travis, William D.
Wydane w Am J Surg Pathol (2016)

Brief Report: Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas

od Guo, Robin, DuBoff, Mariel, Jayakumaran, Gowtham, Kris, Mark G., Ladanyi, Marc, Robson, Mark E., Mandelker, Diana, Zauderer, Marjorie G.
Wydane w J Thorac Oncol (2019)

Allele-specific role of ERBB2 in the oncogenic function of EGFR L861Q in EGFR-mutant lung cancers

od Sato, Hiroki, Offin, Michael, Kubota, Daisuke, Yu, Helena A., Wilhelm, Clare, Toyooka, Shinichi, Somwar, Romel, Kris, Mark G., Ladanyi, Marc
Wydane w J Thorac Oncol (2020)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

od Pao, William, Miller, Vincent A, Politi, Katerina A, Riely, Gregory J, Somwar, Romel, Zakowski, Maureen F, Kris, Mark G, Varmus, Harold
Wydane 2005